For example, the scaffold protein called syntenin, which contains two postsynaptic density protein-95/discs-large/PDZ domains, also presents as a potential new therapeutic target in GBM (Haugaard-Kedstrom et al., 2021). The gene discussed is SDCBP; the disease is glioblastoma.